Structural studies of a surface-entropy reduction mutant of O-GlcNAcase by Males, Alexandra & Davies, Gideon J.
This is a repository copy of Structural studies of a surface-entropy reduction mutant of 
O-GlcNAcase.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/141443/
Version: Published Version
Article:
Males, Alexandra and Davies, Gideon J. orcid.org/0000-0002-7343-776X (2019) Structural
studies of a surface-entropy reduction mutant of O-GlcNAcase. Acta crystallographica. 
Section D, Structural biology. pp. 70-78. ISSN 2059-7983 
https://doi.org/10.1107/s2059798318016595
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
research papers
70 https://doi.org/10.1107/S2059798318016595 Acta Cryst. (2019). D75, 70–78
Received 24 September 2018
Accepted 21 November 2018
Edited by M. Czjzek, Station Biologique de
Roscoff, France
Keywords: O-GlcNAc; O-GlcNAcase;
neurodegeneration; surface-entropy reduction;
crystallization.
PDB reference: surface-entropy reduction
mutant of O-GlcNAcase, 6hki
Supporting information: this article has
supporting information at journals.iucr.org/d
Structural studies of a surface-entropy reduction
mutant of O-GlcNAcase
Alexandra Males and Gideon J. Davies*
Department of Chemistry, University of York, York YO10 5DD, England. *Correspondence e-mail:
gideon.davies@york.ac.uk
The enzyme O-GlcNAcase catalyses the removal of the O-GlcNAc co/post-
translational modification in multicellular eukaryotes. The enzyme has become
of acute interest given the intimate role of O-GlcNAcylation in tau modification
and stability; small-molecular inhibitors of human O-GlcNAcase are under
clinical assessment for the treatment of tauopathies. Given the importance of
structure-based and mechanism-based inhibitor design for O-GlcNAcase, it was
sought to test whether different crystal forms of the human enzyme could be
achieved by surface mutagenesis. Guided by surface-entropy reduction, a
Glu602Ala/Glu605Ala variant [on the Gly11–Gln396/Lys535–Tyr715 construct;
Roth et al. (2017), Nature Chem. Biol. 13, 610–612] was obtained which led to a
new crystal form of the human enzyme. An increase in crystal contacts stabilized
disordered regions of the protein, enabling 88% of the structure to be modelled;
only 83% was possible for the wild-type construct. Although the binding of the
C-terminus was consistent with the wild type, Lys713 in monomer A was bound
in the1 subsite of the symmetry-related monomer A and the active sites of the
B monomers were vacant. The new crystal form presents an opportunity for
enhanced soaking experiments that are essential to understanding the binding
mechanism and substrate specificity of O-GlcNAcase.
1. Introduction
The regulation of O-GlcNAc cycling on thousands of nuclear
and cytoplasmic proteins is coordinated by two enzymes.
O-GlcNAc transferase (OGT) catalyses the addition of
GlcNAc, derived from UDP-GlcNAc, to serine and threonine
residues, and O-GlcNAcase (OGA; CAZY database family
GH84) cleaves O-GlcNAc (Torres & Hart, 1984; Holt & Hart,
1986; Kreppel et al., 1997; Dong & Hart, 1994; Lubas et al.,
1997; Hart et al., 2007). Two isoforms, OGA-L and OGA-S, are
localized to the nucleus/cytoplasm (Comtesse et al., 2001) and
to the surface of lipid droplets, respectively. The reciprocal
relationship between O-phosphorylation and O-glycosylation
on the particular protein tau has been keenly studied in the
context of neurodegeneration (Arnold et al., 1996; Yuzwa et
al., 2008, 2014; Shen et al., 2012; Griffith & Schmitz, 1995; Gao
et al., 2001; Liu et al., 2004). In patients with Alzheimer’s
disease, tau undergoes hyperphosphorylation, causing it to
dissociate from microtubules and aggregate into paired helical
filaments (PHF) and neurofibrillary tangles (NFTs) (Grundke-
Iqbal et al., 1986; Marotta et al., 2015). O-GlcNAc cycling has
also been implicated in tumorigenesis owing to its significant
role in orchestrating a vast number of cellular processes,
for example transcriptional and cytoskeletal regulation, cell
signalling and division, and metabolism (Slawson & Hart,
2011).
Structural characterization of the human O-GlcNAcase
orthologue (HsOGA-L/HsOGA) showed dimer formation
ISSN 2059-7983
both in solution and in the crystal where it has been shown to
be promoted by helix-exchange (Roth et al., 2017) in contrast
to the non-helix-exchanged bacterial dimers (Dennis et al.,
2006; Schimpl et al., 2010; Rao et al., 2006). Composed of two
ordered domains, the N-terminal glycoside hydrolase domain
forms a (/)8 barrel (Li et al., 2012), while the C-terminal
stalk domain (Toleman et al., 2004; He et al., 2014) is composed
of six -helices. 17, consisting of Glu676–Pro694, undergoes a
dimer ‘swap’ (Roth et al., 2017), playing a structural role that
contributes to dimerization (Li, Li, Lu et al., 2017; Elsen et al.,
2017; Roth et al., 2017). Located in a V-shaped cleft formed
between the N-terminal domain of monomer A and the
C-terminal domain of monomer B (Fig. 1a) are the catalytic
residues, Asp174 and Asp175, that initially act as a general
acid and a general base through a two-step retaining
mechanism (Macauley et al., 2005). The terminal domain,
which is not present in OGA-S, has a ‘pseudo’-histone
acetyltransferase activity but was not included in the crystal-
lized construct in the three HsOGA structures as it has a high
degree of disorder.
The recognition mode for glycopeptide substrates has been
explored by obtaining structures of the catalytically inactive
Asp175Asn mutant of HsOGA in complex with a variety of
glycosylated peptides (Li, Li, Lu et al., 2017; Li, Li, Hu et al.,
2017). The peptides bound in each structure can be segregated
into two binding modes with forward or reverse orientations
of the peptide (amino to carboxyl or carboxyl to amino,
respectively) within the binding site. Initially, crystallographic
peptide studies were conducted using an orthologue from the
bacterium Clostridium perfringens (Schimpl et al., 2012;
Mariappa et al., 2015) in complex with TAB1, lamin B1 and
p53 glycosylated peptides. These peptides bound in the
forward direction. Later, Li, Li, Hu et al. (2017) compared the
same glycosylated peptides withHsOGA and they were found
to act in the same way. However, -crystallin B and ELK1
bound in the reverse direction, strengthening the interest in
determining how OGA selects its target (Li, Li, Hu et al.,
2017).
In the ‘apo’ structure, HsOGA11–396+535–715 (thus named
owing to the co-expression of two plasmids containing resi-
dues 11–396 and 535–715), which was published by Roth et al.
(2017) and deposited as PDB entry 5m7r, the C-terminus of
monomer A from residues Pro707 to Tyr715 can be traced in
the reverse direction into the active-site groove of the
symmetry-related molecule of monomer B (Fig. 1b). When
overlaid with the HsOGA–p53 complex (PDB entry 5un8; Li,
Li, Lu et al., 2017), the position of the Tyr715 hydroxyl group
lies directly on top of the O6 of O-GlcNAc.
To conduct biochemical/biophysical studies and rational
drug design, complete and coherent structures are required.
However, the published structures of HsOGA have stretches
of residues that are incomplete (Elsen et al., 2017; Li, Li, Lu et
al., 2017; Li, Li, Hu et al., 2017). For example, the structure
described by Roth et al. (2017) has regions within the
N-terminus (Glu11–Arg58 and Lys341–Thr370) and the
C-terminus (Asp696–Pro706) that are not modelled in the
structure. Expulsion of the C-terminus of HsOGA11–396+535–715
from the active site is required before a competing compound
can bind, therefore making it challenging to conduct crystal-
soaking experiments; this is a problem for weak-binding
compounds/inhibitors.
The work in this paper utilized surface-entropy reduction
(SER) to enhance the structural characterization of HsOGA
and to contribute towards the hypothesis for the substrate-
recognition mode of OGA, in which either the O-GlcNAc
moiety or the peptide sequence is important for recognition.
Using the SERp online server (Goldschmidt et al., 2007),
potential pairs of mutations were identified for HsOGA. The
rational design of mutating clusters of residues on a protein is
a favourable strategy, with the aim of making the protein more
susceptible to crystallization (Derewenda, 2004a,b; Dere-
wenda & Vekilov, 2006; Cooper et al., 2007). Surface-entropy
reduction (SER) is a concept in which flexible, solvent-
exposed residues, primarily lysine and glutamate, are mutated
to alanine to reduce the entropic loss during the packing of the
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Figure 1
HsOGA forms a dimer in solution and in the crystal structure. Monomer
A is shown in blue and monomer B in gold. (a) One of the two active sites
is indicated by intersecting black lines. (b) The C-terminal peptide,
Pro707–Tyr715 in chain B, bound in the active site of monomerA with the
catalytic residues, Asp174/A and Asp175/A, displayed.
protein into a crystalline lattice (Longenecker et al., 2001;
Mateja et al., 2002; Vekilov, 2003; Vekilov et al., 2002).
Following the co-expression strategy of Roth et al. (2017)
using pACYC-Duet-1 Gly11–Gln396 and pET-YSBLIC3C
Lys535–Tyr715 plasmids, the successful pair of mutations
was Glu602Ala/Glu605Ala (HsOGAE602AE605A). Unlike
HsOGA11–396+535–715, the C-terminus of monomer A can be
traced into the active site of the symmetry-related monomer
A, with Lys713 binding in the position of O-GlcNAc.
Furthermore, previously disordered loops had become
ordered and could be built into the final model. Additionally,
the activities and secondary-structure profiles of full-length
HsOGA (HsOGAFL),HsOGA11–396+535–715 andHsOGAE602AE605A
were examined to verify the loss of the ‘pseudo-HAT’ domain
and that the SER mutation did not alter the activity. The
results showed that the SER mutant exhibited similar Km
values to the full-length enzyme, since the mutation is distant
from the active site, highlighting the potential of SER variants
for studying the structural and ligand-binding characteristics
of HsOGA.
2. Materials and methods
2.1. Macromolecular production
The cloning of the constructs has been described previously
(Roth et al., 2017). Homologous DNA for the Lys535–Tyr715
construct, in the vector pET-YSBL-LIC-3C, was mutated
using a Q5 Site-Directed Mutagenesis Kit with Q5 Hot Start
High-Fidelity DNA Polymerase. The forward primer,
A GATAGC gct AAA ATC gct GAA TGG, was designed to
mutate the primary sequence A GATAGC GAA AAA ATC
GAA GAA; the reverse primer was TTA CCC TTG CAG
TTA ACC GAA. NEB 5-alpha competent Escherichia coli
cells were transformed with the Lys535–Tyr715 E602AE605A
construct. The DNAwas extracted and sequenced to verify the
mutation.
The Gly11–Gln396 and Lys535–Tyr715 E602AE605A
constructs in the vectors pACYCDUET-1 and pET-YSBL-
LIC-3C, respectively, were co-transformed into E. coli BL21
(DE3) cells. Luria–Bertani broth was inoculated with a cell
suspension and was incubated at 37C until the OD600 reached
1.0. The cells were induced with 1 mM IPTG and incubated at
16C for 20 h.
The purification of HsOGAE602AE605A followed the same
purification protocol as that of HsOGA11–396+535–715 described
previously (Roth et al., 2017; Supplementary Figs. S1a and
S1b).
2.2. Crystallization
HsOGAE602AE605A was initially crystallized by sitting-drop
vapour diffusion at 15 mg ml1 under condition E11 of the
PACT premier screen from Molecular Dimensions (Newman
et al., 2005): 0.2M sodium citrate tribasic, 20% PEG 3350.
Further optimization of the conditions to 0.2M sodium citrate
tribasic pH 7.5, 17% polyethylene glycol 3350 in a 48-well
MRC MAXI optimization plate improved the crystal shape.
The total volume of the drop was 1 ml and the protein:
reservoir solution ratio was 1:1; the total volume in the
reservoir was 100 ml.
2.3. Data collection and processing
Diffraction images were collected on beamline I04-1 at
Diamond Light Source (DLS). After data collection, the
diffraction images were integrated using the -3dii option in
xia2 (Winter, 2010) and reintegrated using AIMLESS (Evans,
2006; Evans & Murshudov, 2013) from the CCP4 software
suite (Winn et al., 2011). Data-collection and processing
statistics are given in Table 1.
2.4. Structure solution and refinement
Molecular replacement against the coordinates of PDB
entry 5m7r was conducted using MOLREP (Vagin &
Teplyakov, 2010). Refinement of the model was conducted
using multiple rounds of REFMAC (Murshudov et al., 1997,
2011; Pannu et al., 1998; Winn et al., 2003; Vagin et al., 2004;
Nicholls et al., 2012) and manual model building in Coot
(Emsley et al., 2010). Waters were added using Find Waters in
Coot and validated. The data were processed to a resolution of
3.3 A˚ (Table 2).
2.5. Michaelis–Menten kinetics
Michaelis–Menten kinetics were assayed using HsOGAFL
and HsOGA11–396+535–715 as positive controls against the
mutantHsOGAE602AE605A. In a 200 ml reaction volume, 50 nM
protein solution and a serial dilution of the ligand 4-nitro-
phenyl N-acetyl--d-glucosaminide (pNP-GlcNAc) from 1500
to 11.7 mM [dissolved in 2.5% DMSO (final concentration)]
was added to PBS buffer at pH 7.4.
The reaction was monitored at 405 nM continuously using a
Molecular Devices SpectraMax M5 spectrophotometer. The
research papers
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Table 1
Data collection and processing.
Values in parentheses are for the outer shell.
Diffraction source Beamline I04-1, DLS
Wavelength (A˚) 0.9282
Temperature (K) 100
Detector PILATUS 6M-F
Rotation range per image () 0.10
Total rotation range () 360
Exposure time per image (s) 0.040
Space group P3121
a, b, c (A˚) 222.2, 222.2, 72.4
, ,  () 90.0, 90.0, 120.0
Resolution range (A˚) 192.4–3.3 (3.5–3.3)
Total No. of reflections 523842 (75864)
No. of unique reflections 31103 (4440)
Completeness (%) 99.8 (98.6)
Multiplicity 16.8 (17.1)
hI/(I)i 7.3 (1.8)†
Rp.i.m. 0.11 (0.62)
CC1/2 0.99 (0.67)
Overall B factor from Wilson plot (A˚2) 58.53
† The mean I/(I) in the outer shell fell below <2.0 at 3.4 A˚ resolution.
experiment, which was conducted at 25C, was duplicated and
each ligand concentration was repeated in triplicate.
GraphPad Prism v.5 was used to process the data, with
nonlinear regression of Michaelian saturation curves. The
initial velocities were calculated from the linear range of the
reaction-progress curve. A standard curve of 4-nitrophenol
was used to extract a molar extinction coefficient.
2.6. Circular-dichroism spectroscopy
The protein samples were dialysed overnight into 25 mM
sodium phosphate pH 8.0 and diluted to 0.1 mg ml1. The
spectra were recorded at 21C in a QS 248 0.2 mm cuvette with
0.5 s per point and 78 s per read. The wavelength ranged from
195 to 320 nm. The background for each protein was measured
immediately before the experiment in the same cuvette and
values were taken as averages from triplicate reads.
3. Results and discussion
3.1. Comparison of the mutant crystal structure with that of
the wild type
To incorporate protein molecules into a crystal, a thermo-
dynamic cost is endured to bury hydrophobic residues into a
constrained conformation and from the immobilization of the
prevalent flexible hydrophilic side chains on the surface
(Avbelj & Fele, 1998). Reducing the entropic shield can lead
to an increase in the variety of conditions, morphologies and
crystallographic space groups (Parthasarathy et al., 2008; Kim
et al., 2005). Therefore, crystallization conditions were re-
screened using the HsOGAE602AE605A variant; crystals were
obtained in 17% polyethylene glycol 3350, 0.2M sodium
citrate pH 8.0. This is comparable to the wild-type crystal-
lization condition of 0.1–0.2M triammonium citrate pH 6.5–
7.5, 16–24% PEG 3350.
In a different crystal form, flexible loops can become
ordered by making backbone crystal contacts or adopting
preferential conformations (Derewenda, 2004a). The space
group was P3121, which is a lower symmetry group compared
with P43212 for the HsOGA11–396+535–715 structure. The data
statistics are presented in Tables 1 and 2.
Theoretically, SER should lead to an improvement in the
resolution and hence the overall quality of the structure
(Parthasarathy et al., 2008). However, the structure was
determined to a resolution of 3.3 A˚, which was a lower reso-
lution compared with the HsOGA11–396+535–715 and catalyti-
cally inactive mutant structures, possibly owing to the thin-rod
crystal morphology compared with the large trigonal bi-
pyramid wild-type crystals.
A solvent channel can be observed through the crystal
structure (Fig. 2a). The dimers form a trigonal spring such that
the C-terminus of monomer A binds into the active-site
monomer A of a symmetry-related dimer, etc. (Figs. 2a and
2b). Owing to the different crystal contacts made on the
surface of the protein, regions of high disorder could be built
into the structure. 88% of the structure was complete, in
comparison with 83% of the HsOGA11–396+535–715 structure.
The regions of highest disorder in both monomers were
between Lys341 and Thr370, in addition to loops on the
protein surface. After multiple rounds of refinement, the
confidence for the inclusion of residues Lys341–Asp347
increased, enabling further visualization of the disordered
region (Figs. 2c and 2d). The residues that were still disordered
in monomers A and B were Gly11–Gly56, Ser348–Glu369,
Lys535 and Pro707–Tyr715 for monomer B only. In the protein
structures described by Elsen et al. (2017) and Li, Li, Lu et al.
(2017) the residues Lys341–Asp371 in monomerA (PDB entry
5uhk) and Asn335–Val372 in monomer A (PDB entry 5tke),
respectively, were also not observed.
When the N-terminal domains of monomer A from
HsOGAE602AE605A and HsOGA11–396+535–715 were overlapped,
the r.m.s.d. of the N-terminal domains was 1.5 A˚ and the
r.m.s.d. for the C-terminal domains was 7.1 A˚, indicating a
high degree of flexibility in the latter domain (Fig. 2e).
As mentioned, the C-terminus of monomer A was found to
bind into the active site of a symmetry-related monomer A,
aiding the formation of the new crystal packing (Figs. 2b and
3a). Initially, the residues of 17 interact with monomer B in a
domain swap; the residues from Pro694 to Phe703 then bend
back towards the residues of the respective monomer, with
Gln704–Tyr715 binding into the active site (Figs. 3a and 3b).
Electrostatic interactions between the C-terminus of
monomer A and other residues of monomer A, B and a
symmetry-related molecule B stabilize this formation. Pro707
of HsOGAE602AE605A has drastically moved position and faces
in the opposite direction. There are three consecutive prolines
that facilitate the change in direction. Hence, the C-terminus
binds to the active site of the symmetry-related monomer A
rather than monomer B (as in the wild type). The C-terminus
of monomer B could not be built in from Pro707, indicating
that it does not bind into an active site because of the crystal
packing. In HsOGA11–396+535–715, residues Asp696–Pro707 in
monomer A are missing; therefore, the direction of the
peptide is ambiguous. In the natural human sequence, the
pseudo-histone acetyltransferase domain is connected to the
research papers
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Table 2
Structure solution and refinement.
Values in parentheses are for the outer shell.
Resolution range (A˚) 192.4–3.3 (3.5–3.3)
No. of reflections 31064
Final Rcryst 0.17
Final Rfree 0.23
Cruickshank DPI 0.40
No. of non-H atoms
Protein 7877
Water 1
Total 7878
R.m.s. deviations
Bonds (A˚) 0.010
Angles () 1.58
Average B factors (A˚2)
Protein 75
Water 16
Ramachandran plot
Most favoured (%) 92
Allowed (%) 5
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Figure 2
(a, b) Crystal symmetry of HsOGAE602AE605A. (a) The connections made between the dimers show the trigonal solvent channel, with 50% solvent as
calculated from the Matthews coefficient of 2.51 A˚3 Da1 (Kantardjieff & Rupp, 2003; Matthews, 1968). (b) Side view of the repeating trigonal dimers
showing the linking C-terminus of monomer A binding into monomer A of the next dimer complex. The monomers are labelled A and B, with asterisks
indicating the C-termini. (c, d) Disordered loop regions were stabilized in the new crystal form. Monomer A is shown in sea green and monomer B in
brown. (c) The regions in purple were built into theHsOGAE602AE605A structure using PDB entry 5m7r as the template model and were missing from the
wild-type structure. (d) Residues Lys341–Gly347 and the maximum-likelihood/A-weighted 2Fobs  Fcalc map shown in red contoured at 0.12 e A˚
3. (e)
Overlap of the N-terminal monomers A from chain A for both HsOGA11–396+535–715 (monomer A, blue; monomer B, gold) and HsOGAE602AE605A
(monomer A, sea green; monomer B, brown) as calculated by CCP4mg Superpose models. The residue range selected for superposition was Arg59/A–
His395/A.
stalk domain; therefore, binding of the C-terminus in the
active site or alternatively C-termini disorder are possible
artefacts of the removal of the HAT domain and of crystal
packing.
The C-terminal residues Lys713/A and Tyr715/A hydrogen-
bond to and make electrostatic interactions with residues of
the active site (Fig. 3b). Interestingly, the NZ atom of Lys713 is
in the same position as the N2 atom of O-GlcNAc and is
2.97 A˚ away from the O atom of Asp175/A on the symmetry-
related monomer (Fig. 3d). This pushes Tyr715 into the +2
subsite, where it interacts with the O atom of Ser652/B of the
symmetry-related monomer (Fig. 3a). In comparison, the
Tyr715/A hydroxyl group of the wild type lies above O6 of
O-GlcNAc and hydrogen-bonds to the O1 atom of Asp285/B
(Fig. 3c).
In comparison to the crystal structure of HsOGA in
complex with -crystallin B and ELK1 (PDB entries 5vvv and
5vvt, respectively; Li, Li, Lu et al., 2017), the C-terminal
residues are in the same reverse direction as the glycosylated
research papers
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Figure 3
The C-terminus of monomer A binds into the active site of the symmetry-related monomer A. (a) Neighbouring residues in the active site of symmetry-
related monomer A ofHsOGAE602AE605A, with the C-terminal residues bound and the maximum-likelihood/A-weighted 2Fobs Fcalc map shown in red
contoured at 0.17 e A˚3. (b) Surface representation of the active site with the C-terminus bound in a negatively charged pocket. (c) Overlay of Lys713/A
from HsOGAE602AE605A and Tyr715/B from HsOGA11–396+535–715 (in gold) in the binding pocket. (d) Overlay of the C-terminus of chain A of
HsOGAE602AE605A and that of HsOGA in complex with glycosylated p53 peptide (PDB entry 5un8), showing Ser149/E in coral. O-GlcNAc is shown in
yellow. (e) Overlay of Lys713/A fromHsOGAE602AE605AwithHsOGA in complex with glycosylated -crystallin B (PDB entry 5vvv), showing Ser41/B in
purple.
peptides (Fig. 3e). This is in contrast to the structure
containing a glycosylated p53 peptide shown in Fig. 3(d).
The density for all available HsOGA peptide-complex
structures supports the notion that OGA can bind peptides in
both the forward and reverse directions. Comparison between
the different peptide structures shows the versatility of the
active site for different peptides.
3.2. Comparison of the constructs and mutants
To ensure that the structural stabilization had not
occurred owing to a change in the secondary structure of
HsOGAE602AE605A and that the mutation had not affected the
activity of the enzyme, the full-length protein (HsOGAFL),
HsOGA11–396+535–715 and HsOGAE602AE605A underwent
kinetic and secondary-structure analyses.
Comparison of the results for HsOGAFL and
HsOGA11–396+535–715 shows that the split construct has similar
activity to the full-length variant, suggesting that co-expres-
sion of the two domains does not affect the activity (Fig. 4).
Therefore, the ligand-binding data should be an accurate
representation of binding to the full-length protein. When
comparing HsOGA11–396+535–715 and HsOGAE602AE605A, the
values are very similar. The Vmax is higher, indicating an
increase in the reaction rate (Table 3). The increase in Vmax
may be owing to a discrepancy in the enzyme concentration
([E]), as V0 is directly proportional to [E]. The similarity of
Vmax and Km for the mutant and the wild type suggest that the
mutation did not alter the substrate-binding affinity or the
enzyme activity of the protein for its substrate.
The CD spectra show that all of the constructs are
fully folded and the spectra for HsOGA11–396+535–715 and
HsOGAE602AE605A are very similar, suggesting that there is no
change in the composition of the mutant (Fig. 5). The spectral
profile of HsOGAFL differs from those of the split constructs
in that it has a less pronounced minimum in the 222 nm region
and an overall blue-shifted spectrum in the <210 nm region.
This suggests that there could be a lower proportion of -
helical structure and/or higher structural disorder. This links
to the inclusion of the pseudo-HAT domain that is connected
to the C-terminal stalk domain. Since the structure of the
human homologue of this domain is unknown owing to the
inability of HsOGAFL to crystallize, the structure can only be
inferred from the structural homologues from Oceanicola
granulosus and Streptomyces sviceus (He et al., 2014; Rao et al.,
2013). An estimate of the secondary-structure content of the
proteins suggests a decrease of 6.4% in -helical components
and an increase of 3.7% in -sheet components in HsOGAFL
compared with HsOGA11–396+535–715 (Supplementary Table
S1). Homology modelling using crystal structures of the HAT
domain from the bacterial homologue O. granulosus suggests
a similar overall structure minus the acetyltransferase activity
(Rao et al., 2013). However, the data could be skewed by the
inclusion of the linker region to this domain and the potential
difference in the homology model structure. The secondary-
structure contents ofHsOGA11–396+535–715 andHsOGAE602AE605A
are consistent, further confirming that the mutation did not
affect the overall structure.
4. Conclusions
In this study, surface-entropy reduction has been utilized to
produce further structural information on O-GlcNAcase by
the incorporation of residues Ala57–Arg58, Lys341–Asp347,
Thr370, Glu536, Cys596–Gly598, Gly674–Asp675 and
Asp696–Pro707, an increase in the number of observed resi-
dues of 5%. Although the binding of the C-terminus to the
active site may be an artefact of crystallization, it reveals
further details regarding the substrate specificity of OGA, as
peptides have been shown to bind in a bidirectional yet
conserved conformation. The results described in this study
research papers
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Figure 5
Circular-dichroism spectra for the different constructs. The experimental
data in millidegree units were converted to mean residue ellipticity values
with units of deg cm2 dmol1 using the equation given in Ishtikhar et al.
(2014).
Figure 4
Michaelis–Menten curves for the kinetic assay of the HsOGA mutant.
pNP-GlcNAc was used as the substrate at concentrations up to seven
times higher than the Km.
Table 3
Kinetics analysis comparing different HsOGA constructs.
Construct HsOGAFL HsOGA11–396+575–715 HsOGAE602AE605A
Vmax (mM min
1) 2.96  0.07 2.50  0.06 4.62  0.15
Km (mM) 298  15 227  13 230  20
kcat (min
1) 59.1  1.4 49.9  1.2 92.5  3.1
kcat/Km (min
1
mM1) 0.198  0.012 0.219  0.013 0.401  0.038
present an opportunity for further investigation of the binding
orientation of peptides within an SER-modified OGA
enzyme. Given the progression of hOGA inhibitors into
clinical trials, different surface mutants of the enzyme may
afford new routes to drug development.
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